Collateral damage: Contribution of peripheral inflammation to neurodegenerative diseases

Current Topics in Medicinal Chemistry

Volumn 15, Issue 21, 2015, Pages 2193-2210

  Herrera, Antonio J ^a,b   Espinosa Oliva, Ana M ^a,b   Oliva Martín, María J ^a,b   Carrillo Jiménez, Alejandro ^a,b   Venero, José L ^a,b   de Pablos, Rocío M ^a,b  

^a UNIVERSITY OF SEVILLE   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Gut brain axis; Inflammatory bowel disease; Microglia; Neurodegeneration; Parkinson's disease; Peripheral inflammation

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; CHRONIC DISEASE; DEGENERATIVE DISEASE; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFLAMMATION; MACROPHAGE; NONHUMAN; PARKINSON DISEASE; PREVALENCE; PROTEIN EXPRESSION; RISK FACTOR; SIGNAL TRANSDUCTION; ANIMAL; DIETARY SUPPLEMENT; ENCEPHALITIS; GASTROINTESTINAL DISEASE; GENETICS; INFLAMMATORY BOWEL DISEASE; METABOLISM; MICROGLIA; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ALZHEIMER DISEASE; ANIMALS; CHRONIC DISEASE; DIETARY SUPPLEMENTS; ENCEPHALITIS; GASTROINTESTINAL DISEASES; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MICROGLIA; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES;

EID: 84939824848     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150610142027     Document Type: Article

References (270)

1. [1] Daulatzai, M. A. Non-Celiac Gluten Sensitivity Triggers Gut Dys-biosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia. CNS Neurol. Disord. Drug Targets. 2015, 14, 110-131.
2. [2] Daulatzai, M. A. Role of stress, depression, and aging in cognitive decline and Alzheimer's disease. Curr. Top. Behav. Neurosci. 2014, 18, 265-296.
3. [3] Daulatzai, M. A. Chronic functional bowel syndrome enhances gut-brain axis dysfunction, neuroinflammation, cognitive impairment, and vulnerability to dementia. Neurochem. Res., 2014, 39, 624-644.
4. [4] Daulatzai, M. A. Pathogenesis of cognitive dysfunction in patients with obstructive sleep apnea: a hypothesis with emphasis on the nucleus tractus solitarius. Sleep Disord., 2012, 2012, 251096.
5. [5] Daulatzai, M. A. Neurotoxic saboteurs: straws that break the hippo's (hippocampus) back drive cognitive impairment and Alzheimer's Disease. Neurotox. Res., 2013, 24, 407-459.
6. [6] Spielman, L. J.; Little, J. P.; Klegeris, A. Inflammation and insu-lin/IGF-1 resistance as the possible link between obesity and neu-rodegeneration. J. Neuroimmunol., 2014, 273, 8-21.
7. [7] Smith, J. A.; Das, A.; Ray, S. K.; Banik, N. L. Role of pro-inflammatory cytokines released from microglia in neurodegenera-tive diseases. Brain Res. Bull., 2012, 87, 10-20.
8. [8] Soczynska, J. K.; Kennedy, S. H.; Woldeyohannes, H. O.; Liauw, S. S.; Alsuwaidan, M.; Yim, C. Y.; McIntyre, R. S. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. NeuromolecularMed., 2011, 13, 93-116.
9. [9] Simard, A. R.; Soulet, D.; Gowing, G.; Julien, J. P.; Rivest, S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron, 2006, 49, 489-502.
10. [10] Davalos, D.; Grutzendler, J.; Yang, G.; Kim, J. V.; Zuo, Y.; Jung, S.; Littman, D. R.; Dustin, M. L.; Gan, W. B. ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci., 2005, 8, 752-758.
11. [11] Laskin, D. L. Macrophages and inflammatory mediators in chemical toxicity: a battle of forces. Chem. Res. Toxicol., 2009, 22, 1376-1385.
12. [12] Strieter, R. M.; Kasahara, K.; Allen, R.; Showell, H. J.; Standiford, T. J.; Kunkel, S. L. Human neutrophils exhibit disparate chemotac-tic factor gene expression. Biochem. Biophys. Res. Commun., 1990, 173, 725-730.
13. [13] Bryant, R. E.; DesPrez, R. M.; VanWay, M. H.; Rogers, D. E. Studies on human leukocyte motility. I. Effects of alterations in pH, electrolyte concentration, and phagocytosis on leukocyte migration, adhesiveness, and aggregation. J. Exp. Med., 1966, 124, 483-499.
14. [14] Sahan, M.; Sebe, A.; Acikalin, A.; Akpinar, O.; Koc, F.; Ay, M. O.; Gulen, M.; Topal, M.; Satar, S. Acute-phase reactants and cytoki-nes in ischemic stroke: do they have any relationship with short-term mortality? Eur. Rev. Med. Pharmacol. Sci., 2013, 17, 2773-2777.
15. [15] Biffl, W. L.; Moore, E. E.; Moore, F. A.; Barnett, C. C.; Silli-man, C. C.; Peterson, V. M. Interleukin-6 stimulates neutrophil production of platelet-activating factor. J. Leukoc. Biol., 1996, 59, 569-574.
16. [16] Kopf, M.; Baumann, H.; Freer, G.; Freudenberg, M.; Lamers, M.; Kishimoto, T.; Zinkernagel, R.; Bluethmann, H.; Kohler, G. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature, 1994, 368, 339-342.
17. [17] Duff, G. W.; Durum, S. K. Fever and immunoregulation: hyper-thermia, interleukins 1 and 2, and T-cell proliferation. Yale J. Biol. Med., 1982, 55, 437-442.
18. [18] Spielman, L. J.; Little, J. P.; Klegeris, A. Inflammation and insu-lin/IGF-1 resistance as the possible link between obesity and neu-rodegeneration. J. Neuroimmunol., 2014, 273, 8-21.
19. [19] HIRSCH, J. G. Immunity to infectious diseases: review of some concepts of Metchnikoff. Bacteriol. Rev., 1959, 23, 48-60.
20. [20] Rao, X.; Zhong, J.; Sun, Q. The heterogenic properties of mono-cytes/macrophages and neutrophils in inflammatory response in diabetes. Life Sci., 2014, 116, 59-66.
21. [21] Gordon, S. Alternative activation of macrophages. Nat. Rev. Immunol., 2003, 3, 23-35.
22. [22] Mosser, D. M. The many faces of macrophage activation. J. Leukoc. Biol., 2003, 73, 209-212.
23. [23] Murray, P. J.; Allen, J. E.; Biswas, S. K.; Fisher, E. A.; Gilroy, D. W.; Goerdt, S.; Gordon, S.; Hamilton, J. A.; Ivashkiv, L. B.; Lawrence, T.; Locati, M.; Mantovani, A.; Martinez, F. O.; Mege, J. L.; Mosser, D. M.; Natoli, G.; Saeij, J. P.; Schultze, J. L.; Shirey, K. A.; Sica, A.; Suttles, J.; Udalova, I.; van Ginderachter, J. A.; Vogel, S. N.; Wynn, T. A. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity, 2014, 41, 1420.
24. [24] Aggarwal, B. B. Nuclear factor-kappaB: the enemy within. Cancer. Cell, 2004, 6, 203-208.
25. [25] Frank-Cannon, T. C.; Alto, L. T.; McAlpine, F. E.; Tansey, M. G. Does neuroinflammation fan the flame in neurodegenerative diseases? Mol. Neurodegener., 2009, 4, 47-1326-4-47.
26. [26] Meijer, K.; de Vries, M.; Al-Lahham, S.; Bruinenberg, M.; Weening, D.; Dijkstra, M.; Kloosterhuis, N.; van der Leij, R. J.; van der Want, H.; Kroesen, B. J.; Vonk, R.; Rezaee, F. Human primary adipocytes exhibit immune cell function: adipocytes prime inflammation independent of macrophages. PLoS One, 2011, 6, e17154.
27. [27] Bende, R. J.; van Maldegem, F.; van Noesel, C. J. Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas. Haematologica, 2009, 94, 1109-1123.
28. [28] Naugler, W. E.; Karin, M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med., 2008, 14, 109-119.
29. [29] Vandenbroucke, J. P.; Hazevoet, H. M.; Cats, A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective fol-lowup. J. Rheumatol., 1984, 11, 158-161.
30. [30] Zhang, J.; Zhang, Y.; Jin, J.; Li, M.; Xie, K.; Wen, C.; Cheng, R.; Chen, C.; Lu, J. The -1082A/G polymorphism in the Interleukin-10 gene and the risk of rheumatoid arthritis: a meta-analysis. Cytokine, 2011, 56, 351-355.
31. [31] Stahl, E. A.; Raychaudhuri, S.; Remmers, E. F.; Xie, G.; Eyre, S.; Thomson, B. P.; Li, Y.; Kurreeman, F. A.; Zhernakova, A.; Hinks, A.; Guiducci, C.; Chen, R.; Alfredsson, L.; Amos, C. I.; Ardlie, K. G.; BIRAC Consortium; Barton, A.; Bowes, J.; Brouwer, E.; Burtt, N. P.; Catanese, J. J.; Coblyn, J.; Coenen, M. J.; Costenbader, K. H.; Criswell, L. A.; Crusius, J. B.; Cui, J.; de Bakker, P. I.; De Jager, P. L.; Ding, B.; Emery, P.; Flynn, E.; Harrison, P.; Hocking, L. J.; Huizinga, T. W.; Kastner, D. L.; Ke, X.; Lee, A. T.; Liu, X.; Martin, P.; Morgan, A. W.; Padyukov, L.; Posthumus, M. D.; Rad-stake, T. R.; Reid, D. M.; Seielstad, M.; Seldin, M. F.; Shadick, N. A.; Steer, S.; Tak, P. P.; Thomson, W.; van der Helm-van Mil, A. H.; van der Horst-Bruinsma, I. E.; van der Schoot, C. E.; van Riel, P. L.; Weinblatt, M. E.; Wilson, A. G.; Wolbink, G. J.; Wordsworth, B. P.; YEAR Consortium; Wijmenga, C.; Karlson, E. W.; Toes, R. E.; de Vries, N.; Begovich, A. B.; Worthington, J.; Simi-novitch, K. A.; Gregersen, P. K.; Klareskog, L.; Plenge, R. M. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat. Genet., 2010, 42, 508-514.
32. [32] Olefsky, J. M.; Glass, C. K. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol., 2010, 72, 219-246.
33. [33] Lehrke, M.; Reilly, M. P.; Millington, S. C.; Iqbal, N.; Rader, D. J.; Lazar, M. A. An inflammatory cascade leading to hyperresistine-mia in humans. PLoS Med., 2004, 1, e45.
34. [34] Fong, C. H.; Bebien, M.; Didierlaurent, A.; Nebauer, R.; Hussell, T.; Broide, D.; Karin, M.; Lawrence, T. An antiinflammatory role for IKKbeta through the inhibition of "classical" macrophage activation. J. Exp. Med., 2008, 205, 1269-1276.
35. [35] Steinberg, D.; Witztum, J. L. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2010, 30, 2311-2316.
36. [36] Subramanian, M.; Tabas, I. Dendritic cells in atherosclerosis. Semin. Immunopathol., 2014, 36, 93-102.
37. [37] Libby, P.; Ridker, P. M.; Hansson, G. K. Progress and challenges in translating the biology of atherosclerosis. Nature, 2011, 473, 317-325.
38. [38] Leitinger, N.; Schulman, I. G. Phenotypic polarization of macro-phages in atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2013, 33, 1120-1126.
39. [39] Leone, V. A.; Cham, C. M.; Chang, E. B. Diet, gut microbes, and genetics in immune function: can we leverage our current knowledge to achieve better outcomes in inflammatory bowel diseases? Curr. Opin. Immunol., 2014, 31C, 16-23.
40. [40] Montgomery, S. M.; Ekbom, A. Epidemiology of inflammatory bowel disease. Curr. Opin. Gastroenterol, 2002, 18, 416-420.
41. [41] Hisamatsu, T.; Kanai, T.; Mikami, Y.; Yoneno, K.; Matsuoka, K.; Hibi, T. Immune aspects of the pathogenesis of inflammatory bowel disease. Pharmacol. Ther., 2013, 137, 283-297.
42. [42] Baumgart, D. C.; Carding, S. R. Inflammatory bowel disease: cause and immunobiology. Lancet, 2007, 369, 1627-1640.
43. [43] Xavier, R. J.; Podolsky, D. K. Unravelling the pathogenesis of inflammatory bowel disease. Nature, 2007, 448, 427-434.
44. [44] Kucharzik, T.; Maaser, C.; Lugering, A.; Kagnoff, M.; Mayer, L.; Targan, S.; Domschke, W. Recent understanding of IBD patho- genesis: implications for future therapies. Inflamm. Bowel Dis., 2006, 12, 1068-1083.
45. [45] Ahmad, T.; Tamboli, C. P.; Jewell, D.; Colombel, J. F. Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology, 2004, 126, 1533-1549.
46. [46] Van Assche, G.; Geboes, K.; Rutgeerts, P. Medical therapy for Crohn's disease strictures. Inflamm. Bowel Dis., 2004, 10, 55-60.
47. [47] Longo, W. E.; Virgo, K. S.; Bahadursingh, A. N.; Johnson, F. E. Patterns of disease and surgical treatment among United States veterans more than 50 years of age with ulcerative colitis. Am. J. Surg., 2003, 186, 514-518.
48. [48] Cosnes, J.; Cattan, S.; Blain, A.; Beaugerie, L.; Carbonnel, F.; Parc, R.; Gendre, J. P. Long-term evolution of disease behavior of Crohn's disease. Inflamm. Bowel Dis., 2002, 8, 244-250.
49. [49] Lawrance, I. C.; Rogler, G.; Bamias, G.; Breynaert, C.; Florhol-men, J.; Pellino, G.; Reif, S.; Speca, S.; Latella, G. Cellular and molecular mediators of intestinal fibrosis. J. Crohns Colitis, 2014, Oct 8. pii: S1873-9946(14)00289-X.
50. [50] Wuwongse, S.; Chang, R. C.; Law, A. C. The putative neurodegen-erative links between depression and Alzheimer's disease. Prog. Neurobiol., 2010, 91, 362-375.
51. [51] Wenk, G. L. Neuropathologic changes in Alzheimer's disease. J. Clin. Psychiatry, 2003, 64 Suppl 9, 7-10.
52. [52] Sakono, M.; Zako, T. Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J., 2010, 277, 1348-1358.
53. [53] Koffie, R. M.; Hyman, B. T.; Spires-Jones, T. L. Alzheimer's disease: synapses gone cold. Mol. Neurodegener, 2011, 6, 63-1326-663.
54. [54] Price, K. A.; Varghese, M.; Sowa, A.; Yuk, F.; Brautigam, H.; Ehrlich, M. E.; Dickstein, D. L. Altered synaptic structure in the hippocampus in a mouse model of Alzheimer's disease with soluble amyloid-beta oligomers and no plaque pathology. Mol. Neurodegener, 2014, 9, 41-1326-9-41.
55. [55] Jacobsen, J. S.; Wu, C. C.; Redwine, J. M.; Comery, T. A.; Arias, R.; Bowlby, M.; Martone, R.; Morrison, J. H.; Pangalos, M. N.; Reinhart, P. H.; Bloom, F. E. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A, 2006, 103, 5161-5166.
56. [56] Lefterov, I.; Fitz, N. F.; Cronican, A.; Lefterov, P.; Staufenbiel, M.; Koldamova, R. Memory deficits in APP23/Abca1+/- mice correlate with the level of Abeta oligomers. ASN Neuro., 2009,1, 10.1042/AN20090015.
57. [57] Haass, C.; Selkoe, D. J. Soluble protein oligomers in neurodegen-eration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol., 2007, 8, 101-112.
58. [58] Hardy, J.; Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002, 297, 353-356.
59. [59] Ittner, L. M.; Gotz, J. Amyloid-beta and tau-- a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci., 2011, 12, 65-72.
60. [60] Gotz, J.; Streffer, J. R.; David, D.; Schild, A.; Hoerndli, F.; Pen- nanen, L.; Kurosinski, P.; Chen, F. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol. Psychiatry., 2004, 9, 664-683.
61. [61] Roy, S.; Zhang, B.; Lee, V. M.; Trojanowski, J. Q. Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathol., 2005, 109, 5-13.
62. [62] Trojanowski, J. Q.; Smith, A. B.; Huryn, D.; Lee, V. M. Microtu- bule-stabilising drugs for therapy of Alzheimer's disease and other neurodegenerative disorders with axonal transport impairments. Expert Opin. Pharmacother., 2005, 6, 683-686.
63. [63] Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholo-denko, D.; Lee, M.; Liao, Z.; Lieberburg, I.; Motter, R.; Mutter, L.; Soriano, F.; Shopp, G.; Vasquez, N.; Vandevert, C.; Walker, S.; Wogulis, M.; Yednock, T.; Games, D.; Seubert, P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 1999, 400, 173-177.
64. [64] Gilman, S.; Koller, M.; Black, R. S.; Jenkins, L.; Griffith, S. G.; Fox, N. C.; Eisner, L.; Kirby, L.; Rovira, M. B.; Forette, F.; Or-gogozo, J. M.; AN1792(QS-21)-201 Study Team Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 2005, 64, 1553-1562.
65. [65] Galimberti, D.; Ghezzi, L.; Scarpini, E. Immunotherapy against amyloid pathology in Alzheimer's disease. J. Neurol. Sci., 2013, 333, 50-54.
66. [66] Spencer, B.; Masliah, E. Immunotherapy for Alzheimer's disease: past, present and future. Front. Aging Neurosci., 2014, 6, 114.
67. [67] Doody, R. S.; Thomas, R. G.; Farlow, M.; Iwatsubo, T.; Vellas, B.; Joffe, S.; Kieburtz, K.; Raman, R.; Sun, X.; Aisen, P. S.; Siemers, E.; Liu-Seifert, H.; Mohs, R.; Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med., 2014, 370, 311-321.
68. [68] Salloway, S.; Sperling, R.; Fox, N. C.; Blennow, K.; Klunk, W.; Raskind, M.; Sabbagh, M.; Honig, L. S.; Porsteinsson, A. P.; Ferris, S.; Reichert, M.; Ketter, N.; Nejadnik, B.; Guenzler, V.; Mi-loslavsky, M.; Wang, D.; Lu, Y.; Lull, J.; Tudor, I. C.; Liu, E.; Grundman, M.; Yuen, E.; Black, R.; Brashear, H. R.; Bapineuzu-mab 301 and 302 Clinical Trial Investigators Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med., 2014, 370, 322-333.
69. [69] Yankner, B. A.; Duffy, L. K.; Kirschner, D. A. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science, 1990, 250, 279-282.
70. [70] Heneka, M. T.; O'Banion, M. K.; Terwel, D.; Kummer, M. P. Neuroinflammatory processes in Alzheimer's disease. J. Neural Transm., 2010, 117, 919-947.
71. [71] Block, M. L.; Zecca, L.; Hong, J. S. Microglia-mediated neurotox-icity: uncovering the molecular mechanisms. Nat. Rev. Neurosci., 2007, 8, 57-69.
72. [72] Glass, C. K.; Saijo, K.; Winner, B.; Marchetto, M. C.; Gage, F. H. Mechanisms underlying inflammation in neurodegeneration. Cell, 2010, 140, 918-934.
73. [73] Block, M. L.; Hong, J. S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol., 2005, 76, 77-98.
74. [74] Frautschy, S. A.; Yang, F.; Irrizarry, M.; Hyman, B.; Saido, T. C.; Hsiao, K.; Cole, G. M. Microglial response to amyloid plaques in APPsw transgenic mice. Am. J. Pathol., 1998, 152, 307-317.
75. [75] Itagaki, S.; McGeer, P. L.; Akiyama, H.; Zhu, S.; Selkoe, D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J. Neuroimmunol., 1989, 24, 173-182.
76. [76] Okello, A.; Edison, P.; Archer, H. A.; Turkheimer, F. E.; Kennedy, J.; Bullock, R.; Walker, Z.; Kennedy, A.; Fox, N.; Rossor, M.; Brooks, D. J. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology., 2009, 72, 56-62.
77. [77] Edison, P.; Archer, H. A.; Gerhard, A.; Hinz, R.; Pavese, N.; Turk- heimer, F. E.; Hammers, A.; Tai, Y. F.; Fox, N.; Kennedy, A.; Ros-sor, M.; Brooks, D. J. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol. Dis., 2008, 32, 412-419.
78. [78] Cagnin, A.; Brooks, D. J.; Kennedy, A. M.; Gunn, R. N.; Myers, R.; Turkheimer, F. E.; Jones, T.; Banati, R. B. In-vivo measurement of activated microglia in dementia. Lancet, 2001, 358, 461-467.
79. [79] Walker, D. G.; Lue, L. F. Investigations with cultured human mi-croglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases. J. Neurosci. Res., 2005, 81, 412-425.
80. [80] Kim, S. U.; de Vellis, J. Microglia in health and disease. J. Neuro-sci. Res., 2005, 81, 302-313.
81. [81] Yip, A. G.; Green, R. C.; Huyck, M.; Cupples, L. A.; Farrer, L. A.; MIRAGE Study Group Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study. BMC Geriatr., 2005, 5, 2.
82. [82] Veld, B. A.; Ruitenberg, A.; Hofman, A.; Launer, L. J.; van Duijn, C. M.; Stijnen, T.; Breteler, M. M.; Stricker, B. H. Nonster- oidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med., 2001, 345, 1515-1521.
83. [83] Anthony, J. C.; Breitner, J. C.; Zandi, P. P.; Meyer, M. R.; Jura- sova, I.; Norton, M. C.; Stone, S. V. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache Coun study. Neurology, 2000, 54, 2066-2071.
84. [84] Stewart, W. F.; Kawas, C.; Corrada, M.; Metter, E. J. Risk of A heimer's disease and duration of NSAID use. Neurology, 1997, 4 626-632.
85. [85] Qin, S.; Colin, C.; Hinners, I.; Gervais, A.; Cheret, C.; Mallat, System Xc- and apolipoprotein E expressed by microglia have o posite effects on the neurotoxicity of amyloid-beta peptide 1-40. Neurosci., 2006, 26, 3345-3356.
86. [86] Combs, C. K.; Karlo, J. C.; Kao, S. C.; Landreth, G. E. be Amyloid stimulation of microglia and monocytes results in TNF pha-dependent expression of inducible nitric oxide synthase a neuronal apoptosis. J. Neurosci., 2001, 21, 1179-1188.
87. [87] Meyer-Luehmann, M.; Spires-Jones, T. L.; Prada, C.; Garc Alloza, M.; de Calignon, A.; Rozkalne, A.; Koenigsknecht-Talbo J.; Holtzman, D. M.; Bacskai, B. J.; Hyman, B. T. Rapid appe ance and local toxicity of amyloid-beta plaques in a mouse mo of Alzheimer's disease. Nature, 2008, 451, 720-724.
88. [88] Fuhrmann, M.; Bittner, T.; Jung, C. K.; Burgold, S.; Page, R. M.; Mitteregger, G.; Haass, C.; LaFerla, F. M.; Kretzschmar, H.; Herms, J. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat. Neurosci., 2010, 13, 411-413.
89. [89] Chapman, G. A.; Moores, K.; Harrison, D.; Campbell, C. A.; Ste art, B. R.; Strijbos, P. J. Fractalkine cleavage from neuronal me branes represents an acute event in the inflammatory response excitotoxic brain damage. J. Neurosci., 2000, 20, RC87
90. [90] Harrison, J. K.; Jiang, Y.; Chen, S.; Xia, Y.; Maciejewski, D.; McNamara, R. K.; Streit, W. J.; Salafranca, M. N.; Adhikari, S.; Thompson, D. A.; Botti, P.; Bacon, K. B.; Feng, L. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc. Natl. Acad. Sci. U. S. A., 1998, 95, 10896-10901.
91. [91] Meyer-Luehmann, M.; Spires-Jones, T. L.; Prada, C.; Garc Alloza, M.; de Calignon, A.; Rozkalne, A.; Koenigsknecht-Talbo J.; Holtzman, D. M.; Bacskai, B. J.; Hyman, B. T. Rapid appe ance and local toxicity of amyloid-beta plaques in a mouse mo of Alzheimer's disease. Nature, 2008, 451, 720-724.
92. [92] Babcock, A. A.; Kuziel, W. A.; Rivest, S.; Owens, T. Chemoki expression by glial cells directs leukocytes to sites of axonal inju in the CNS. J. Neurosci, 2003, 23, 7922-7930.
93. [93] Izikson, L.; Klein, R. S.; Charo, I. F.; Weiner, H. L.; Luster, A. Resistance to experimental autoimmune encephalomyelitis in mi lacking the CC chemokine receptor (CCR)2. J. Exp. Med., 2000 192, 1075-1080.
94. [94] El Khoury, J.; Toft, M.; Hickman, S. E.; Means, T. K.; Terada, K.; Geula, C.; Luster, A. D. Ccr2 deficiency impairs microglial acc mulation and accelerates progression of Alzheimer-like disea Nat. Med., 2007, 13, 432-438.
95. [95] Liu, Y.; Walter, S.; Stagi, M.; Cherny, D.; Letiembre, M.; Schu Schaeffer, W.; Heine, H.; Penke, B.; Neumann, H.; Fassbender, LPS receptor (CD14): a receptor for phagocytosis of Alzheime amyloid peptide. Brain, 2005, 128, 1778-1789.
96. [96] Rogers, J.; Strohmeyer, R.; Kovelowski, C. J.; Li, R. Microglia a inflammatory mechanisms in the clearance of amyloid beta pepti. Glia, 2002, 40, 260-269.
97. [97] Nagele, R. G.; Wegiel, J.; Venkataraman, V.; Imaki, H.; Wang, C.; Wegiel, J. Contribution of glial cells to the development amyloid plaques in Alzheimer's disease. Neurobiol. Aging, 2000 25, 663-674.
98. [98] Simard, A. R.; Soulet, D.; Gowing, G.; Julien, J. P.; Rivest, S. Bo marrow-derived microglia play a critical role in restricting sen plaque formation in Alzheimer's disease. Neuron, 2006, 49, 489-502.
99. [99] Iliff, J. J.; Wang, M.; Liao, Y.; Plogg, B. A.; Peng, W.; Gunderse G. A.; Benveniste, H.; Vates, G. E.; Deane, R.; Goldman, S.; Nagelhus, E. A.; Nedergaard, M. A paravascular pathway faci tates CSF flow through the brain parenchyma and the clearance interstitial solutes, including amyloid beta. Sci. Transl. Med., 2012, 147ra111
100. [100] Iliff, J. J.; Lee, H.; Yu, M.; Feng, T.; Logan, J.; Nedergaard, M Benveniste, H. Brain-wide pathway for waste clearance captur by contrast-enhanced MRI. J. Clin. Invest., 2013, 123, 1299-1309
101. [101] Iliff, J. J.; Wang, M.; Zeppenfeld, D. M.; Venkataraman, A.; Plo B. A.; Liao, Y.; Deane, R.; Nedergaard, M. Cerebral arterial pul tion drives paravascular CSF-interstitial fluid exchange in the mur- ine brain. J. Neurosci., 2013, 33, 18190-18199.
102. [102] Iliff, J. J.; Chen, M. J.; Plog, B. A.; Zeppenfeld, D. M.; Soltero, M.; Yang, L.; Singh, I.; Deane, R.; Nedergaard, M. Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. J. Neurosci., 2014, 34, 16180-16193.
103. [103] Schroder, K.; Tschopp, J. The inflammasomes. Cell, 2010, 140, 821-832.
104. [104] Heneka, M. T.; Kummer, M. P.; Stutz, A.; Delekate, A.; Schwartz, S.; Vieira-Saecker, A.; Griep, A.; Axt, D.; Remus, A.; Tzeng, T. C.; Gelpi, E.; Halle, A.; Korte, M.; Latz, E.; Golenbock, D. T. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature, 2013, 493, 674-678.
105. [105] Shi, J.; Johansson, J.; Woodling, N. S.; Wang, Q.; Montine, T. J.; Andreasson, K. The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J. Immunol., 2010, 184, 7207-7218.
106. [106] Woodling, N. S.; Wang, Q.; Priyam, P. G.; Larkin, P.; Shi, J.; Johansson, J. U.; Zagol-Ikapitte, I.; Boutaud, O.; Andreasson, K. I. Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling. J. Neurosci., 2014, 34, 5882-5894.
107. [107] Liu, S.; Liu, Y.; Hao, W.; Wolf, L.; Kiliaan, A. J.; Penke, B.; Rube, C. E.; Walter, J.; Heneka, M. T.; Hartmann, T.; Menger, M. D.; Fassbender, K. TLR2 is a primary receptor for Alzheimer's amyloid beta peptide to trigger neuroinflammatory activation. J. Immunol., 2012, 188, 1098-1107.
108. [108] Hao, W.; Liu, Y.; Liu, S.; Walter, S.; Grimm, M. O.; Kiliaan, A. J.; Penke, B.; Hartmann, T.; Rube, C. E.; Menger, M. D.; Fassbender, K. Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology. Brain, 2011, 134, 278-292.
109. [109] Liu, Y.; Liu, X.; Hao, W.; Decker, Y.; Schomburg, R.; Fulop, L.; Pasparakis, M.; Menger, M. D.; Fassbender, K. IKKbeta deficiency in myeloid cells ameliorates Alzheimer's disease-related symptoms and pathology. J. Neurosci., 2014, 34, 12982-12999.
110. [110] Obeso, J. A.; Rodriguez-Oroz, M. C.; Rodriguez, M.; Lanciego, J. L.; Artieda, J.; Gonzalo, N.; Olanow, C. W. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci., 2000, 23, S8-19.
111. [111] Hardy, J.; Cai, H.; Cookson, M. R.; Gwinn-Hardy, K.; Singleton, A. Genetics of Parkinson's disease and parkinsonism. Ann. Neurol., 2006, 60, 389-398.
112. [112] Mouradian, M. M. Recent advances in the genetics and pathogene-sis of Parkinson disease. Neurology, 2002, 58, 179-185.
113. [113] Ryan, B. J.; Hoek, S.; Fon, E. A.; Wade-Martins, R. Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. Trends Biochem. Sci., 2015, 40, 200-210.
114. [114] Masliah, E.; Rockenstein, E.; Adame, A.; Alford, M.; Crews, L.; Hashimoto, M.; Seubert, P.; Lee, M.; Goldstein, J.; Chilcote, T.; Games, D.; Schenk, D. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron, 2005, 46, 857-868.
115. [115] Masliah, E.; Rockenstein, E.; Mante, M.; Crews, L.; Spencer, B.; Adame, A.; Patrick, C.; Trejo, M.; Ubhi, K.; Rohn, T. T.; Mueller-Steiner, S.; Seubert, P.; Barbour, R.; McConlogue, L.; Buttini, M.; Games, D.; Schenk, D. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One, 2011, 6, e19338.
116. [116] Bae, E. J.; Lee, H. J.; Rockenstein, E.; Ho, D. H.; Park, E. B.; Yang, N. Y.; Desplats, P.; Masliah, E.; Lee, S. J. Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J. Neurosci., 2012, 32, 13454-13469.
117. [117] Games, D.; Valera, E.; Spencer, B.; Rockenstein, E.; Mante, M.; Adame, A.; Patrick, C.; Ubhi, K.; Nuber, S.; Sacayon, P.; Zago, W.; Seubert, P.; Barbour, R.; Schenk, D.; Masliah, E. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. J. Neurosci., 2014, 34, 9441-9454.
118. [118] Langston, J. W.; Forno, L. S.; Tetrud, J.; Reeves, A. G.; Kaplan, J. A.; Karluk, D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol., 1999, 46, 598-605.
119. [119] McGeer, P. L.; Itagaki, S.; McGeer, E. G. Expression of the histo-compatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol., 1988, 76, 550-557.
120. [120] Mogi, M.; Harada, M.; Narabayashi, H.; Inagaki, H.; Minami, M.; Nagatsu, T. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci. Lett., 1996, 211, 13-16.
121. [121] Wahner, A. D.; Sinsheimer, J. S.; Bronstein, J. M.; Ritz, B. Inflammatory cytokine gene polymorphisms and increased risk of Parkinson disease. Arch. Neurol., 2007, 64, 836-840.
122. [122] Bialecka, M.; Klodowska-Duda, G.; Kurzawski, M.; Slawek, J.; Gorzkowska, A.; Opala, G.; Bialecki, P.; Sagan, L.; Drozdzik, M. Interleukin-10 (IL10) and tumor necrosis factor alpha (TNF) gene polymorphisms in Parkinson's disease patients. Parkinsonism Re- lat. Disord., 2008, 14, 636-640.
123. [123] Ahmed, I.; Tamouza, R.; Delord, M.; Krishnamoorthy, R.; Tzourio, C.; Mulot, C.; Nacfer, M.; Lambert, J. C.; Beaune, P.; Laurent-Puig, P.; Loriot, M. A.; Charron, D.; Elbaz, A. Association between Parkinson's disease and the HLA-DRB1 locus. Mov. Disord., 2012, 27, 1104-1110.
124. [124] Hamza, T. H.; Zabetian, C. P.; Tenesa, A.; Laederach, A.; Mon- timurro, J.; Yearout, D.; Kay, D. M.; Doheny, K. F.; Paschall, J.; Pugh, E.; Kusel, V. I.; Collura, R.; Roberts, J.; Griffith, A.; Samii, A.; Scott, W. K.; Nutt, J.; Factor, S. A.; Payami, H. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat. Genet., 2010, 42, 781-785.
125. [125] Gao, H. M.; Zhou, H.; Zhang, F.; Wilson, B. C.; Kam, W.; Hong, J. S. HMGB1 acts on microglia Mac1 to mediate chronic neuroin-flammation that drives progressive neurodegeneration. J. Neurosci., 2011, 31, 1081-1092.
126. [126] McGeer, P. L.; Schwab, C.; Parent, A.; Doudet, D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann. Neurol., 2003, 54, 599-604.
127. [127] Machado, A.; Herrera, A. J.; Venero, J. L.; Santiago, M.; de Pablos, R. M.; Villaran, R. F.; Espinosa-Oliva, A. M.; Arguelles, S.; Sarmiento, M.; Delgado-Cortes, M. J.; Maurino, R.; Cano, J. Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons. ISRNNeurol., 2011, 2011, 476158.
128. [128] Herrera, A. J.; Castaño, A.; Venero, J. L.; Cano, J.; Machado, A. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol. Dis., 2000, 7, 429-447.
129. [129] Castaño, A.; Herrera, A. J.; Cano, J.; Machado, A. Lipopolysaccha-ride intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J. Neurochem., 1998, 70, 1584-1592.
130. [130] Castaño, A.; Herrera, A. J.; Cano, J.; Machado, A. The degenerative effect of a single intranigral injection of LPS on the dopa-minergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J. Neurochem., 2002, 81, 150-157.
131. [131] Block, M. L.; Zecca, L.; Hong, J. S. Microglia-mediated neurotox-icity: uncovering the molecular mechanisms. Nat. Rev. Neurosci., 2007, 8, 57-69.
132. [132] Burguillos, M. A.; Deierborg, T.; Kavanagh, E.; Persson, A.; Hajji, N.; Garcia-Quintanilla, A.; Cano, J.; Brundin, P.; Englund, E.; Venero, J. L.; Joseph, B. Caspase signalling controls microglia activation and neurotoxicity. Nature, 2011, 472, 319-324.
133. [133] Qin, L.; Liu, Y.; Hong, J. S.; Crews, F. T. NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminer-gic neurodegeneration following systemic LPS administration. Glia, 2013, 61, 855-868.
134. [134] Hirsch, E. C.; Vyas, S.; Hunot, S. Neuroinflammation in Parkinson's disease. Parkinsonism Relat. Disord., 2012, 18 Suppl 1, S210-2.
135. [135] Hirsch, E. C.; Hunot, S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol., 2009, 8, 382-397.
136. [136] Gao, H. M.; Hong, J. S. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol., 2008, 29, 357-365.
137. [137] Block, M. L.; Hong, J. S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol., 2005, 76, 77-98.
138. [138] Barnum, C. J.; Tansey, M. G. Modeling neuroinflammatory patho-genesis of Parkinson's disease. Prog. Brain Res., 2010, 184, 113-132.
139. [139] Wu, D. C.; Teismann, P.; Tieu, K.; Vila, M.; Jackson-Lewis, V.; Ischiropoulos, H.; Przedborski, S. NADPH oxidase mediates oxida-tive stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A, 2003, 100, 6145-6150.
140. [140] Wang, Q.; Chu, C. H.; Oyarzabal, E.; Jiang, L.; Chen, S. H.; Wilson, B.; Qian, L.; Hong, J. S. Subpicomolar diphenyleneiodonium inhibits microglial NADPH oxidase with high specificity and shows great potential as a therapeutic agent for neurodegenerative diseases. Glia. 2014, 62, 2034-2043.
141. [141] McCoy, M. K.; Ruhn, K. A.; Martinez, T. N.; McAlpine, F. E.; Blesch, A.; Tansey, M. G. Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. Mol. Ther., 2008, 16, 1572-1579.
142. [142] McCoy, M. K.; Martinez, T. N.; Ruhn, K. A.; Szymkowski, D. E.; Smith, C. G.; Botterman, B. R.; Tansey, K. E.; Tansey, M. G. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopa-minergic neurons in models of Parkinson's disease. J. Neurosci., 2006, 26, 9365-9375.
143. [143] Barnum, C. J.; Chen, X.; Chung, J.; Chang, J.; Williams, M.; Grigoryan, N.; Tesi, R. J.; Tansey, M. G. Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro(R)1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats. J. Parkinsons Dis., 2014, 4, 349-360.
144. [144] Harms, A. S.; Cao, S.; Rowse, A. L.; Thome, A. D.; Li, X.; Mangieri, L. R.; Cron, R. Q.; Shacka, J. J.; Raman, C.; Standaert, D. G. MHCII is required for alpha-synuclein-induced activation of mi-croglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J. Neurosci., 2013, 33, 9592-9600.
145. [145] Zimprich, A.; Biskup, S.; Leitner, P.; Lichtner, P.; Farrer, M.; Lincoln, S.; Kachergus, J.; Hulihan, M.; Uitti, R. J.; Calne, D. B.; Stoessl, A. J.; Pfeiffer, R. F.; Patenge, N.; Carbajal, I. C.; Vieregge, P.; Asmus, F.; Muller-Myhsok, B.; Dickson, D. W.; Meitinger, T.; Strom, T. M.; Wszolek, Z. K.; Gasser, T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron, 2004, 44, 601-607.
146. [146] Paisan-Ruiz, C.; Jain, S.; Evans, E. W.; Gilks, W. P.; Simon, J.; van der Brug, M.; Lopez de Munain, A.; Aparicio, S.; Gil, A. M.; Khan, N.; Johnson, J.; Martinez, J. R.; Nicholl, D.; Carrera, I. M.; Pena, A. S.; de Silva, R.; Lees, A.; Marti-Masso, J. F.; Perez-Tur, J.; Wood, N. W.; Singleton, A. B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron, 2004, 44, 595-600.
147. [147] Liu, Z.; Lee, J.; Krummey, S.; Lu, W.; Cai, H.; Lenardo, M. J. The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat. Immunol., 2011, 12, 1063-1070.
148. [148] Aliprantis, A. O.; Glimcher, L. H. NFATc1 in inflammatory and musculoskeletal conditions. Adv. Exp. Med. Biol., 2010, 658, 6975.
149. [149] Lin, X.; Parisiadou, L.; Gu, X. L.; Wang, L.; Shim, H.; Sun, L.; Xie, C.; Long, C. X.; Yang, W. J.; Ding, J.; Chen, Z. Z.; Gallant, P. E.; Tao-Cheng, J. H.; Rudow, G.; Troncoso, J. C.; Liu, Z.; Li, Z.; Cai, H. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant al- pha-synuclein. Neuron, 2009, 64, 807-827.
150. [150] Moehle, M. S.; Webber, P. J.; Tse, T.; Sukar, N.; Standaert, D. G.; DeSilva, T. M.; Cowell, R. M.; West, A. B. LRRK2 inhibition attenuates microglial inflammatory responses. J. Neurosci., 2012, 32, 1602-1611.
151. [151] Kirik, D.; Rosenblad, C.; Burger, C.; Lundberg, C.; Johansen, T. E.; Muzyczka, N.; Mandel, R. J.; Bjorklund, A. Parkinson-like neu-rodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci., 2002, 22, 2780-2791.
152. [152] Daher, J. P.; Volpicelli-Daley, L. A.; Blackburn, J. P.; Moehle, M. S.; West, A. B. Abrogation of alpha-synuclein-mediated dopa-minergic neurodegeneration in LRRK2-deficient rats. Proc. Natl. Acad. Sci. U. S. A, 2014, 111, 9289-9294.
153. [153] Moehle, M. S.; Webber, P. J.; Tse, T.; Sukar, N.; Standaert, D. G.; DeSilva, T. M.; Cowell, R. M.; West, A. B. LRRK2 inhibition at- tenuates microglial inflammatory responses. J. Neurosci., 2012, 32, 1602-1611.
154. [154] Gillardon, F.; Schmid, R.; Draheim, H. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proin-flammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience, 2012, 208, 41-48.
155. [155] Stolp, H. B.; Dziegielewska, K. M. Review: Role of developmental inflammation and blood-brain barrier dysfunction in neurodevel-opmental and neurodegenerative diseases. Neuropathol. Appl. Neu-robiol., 2009, 35, 132-146.
156. [156] Palin, K.; Cunningham, C.; Forse, P.; Perry, V. H.; Platt, N. Systemic inflammation switches the inflammatory cytokine profile in CNS Wallerian degeneration. Neurobiol. Dis., 2008, 30, 19-29.
157. [157] Perry, V. H.; Cunningham, C.; Holmes, C. Systemic infections and inflammation affect chronic neurodegeneration. Nat. Rev. Immunol., 2007, 7, 161-167.
158. [158] Spencer, S. J.; Mouihate, A.; Pittman, Q. J. Peripheral inflammation exacerbates damage after global ischemia independently of temperature and acute brain inflammation. Stroke, 2007, 38, 1570-1577.
159. [159] McColl, B. W.; Rothwell, N. J.; Allan, S. M. Systemic inflammation alters the kinetics of cerebrovascular tight junction disruption after experimental stroke in mice. J. Neurosci., 2008, 28, 9451-9462.
160. [160] McColl, B. W.; Rothwell, N. J.; Allan, S. M. Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms. J. Neurosci., 2007, 27, 4403-4412.
161. [161] Cunningham, C.; Wilcockson, D. C.; Campion, S.; Lunnon, K.; Perry, V. H. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J. Neurosci., 2005, 25, 9275-9284.
162. [162] Cunningham, C.; Wilcockson, D. C.; Boche, D.; Perry, V. H. Comparison of inflammatory and acute-phase responses in the brain and peripheral organs of the ME7 model of prion disease. J. Virol., 2005, 79, 5174-5184.
163. [163] Tilvis, R. S.; Kahonen-Vare, M. H.; Jolkkonen, J.; Valvanne, J.; Pitkala, K. H.; Strandberg, T. E. Predictors of cognitive decline and mortality of aged people over a 10-year period. J. Gerontol. A Biol. Sci. Med. Sci., 2004, 59, 268-274.
164. [164] Combrinck, M. I.; Perry, V. H.; Cunningham, C. Peripheral infection evokes exaggerated sickness behaviour in pre-clinical murine prion disease. Neuroscience, 2002, 112, 7-11.
165. [165] Cunningham, C.; Campion, S.; Teeling, J.; Felton, L.; Perry, V. H. The sickness behaviour and CNS inflammatory mediator profile induced by systemic challenge of mice with synthetic double- stranded RNA (poly I:C). Brain Behav. Immun., 2007, 21, 490-502.
166. [166] Laye, S.; Parnet, P.; Goujon, E.; Dantzer, R. Peripheral administration of lipopolysaccharide induces the expression of cytokine transcripts in the brain and pituitary of mice. Brain Res. Mol. Brain Res., 1994, 27, 157-162.
167. [167] Stalder, A. K.; Ermini, F.; Bondolfi, L.; Krenger, W.; Burbach, G. J.; Deller, T.; Coomaraswamy, J.; Staufenbiel, M.; Landmann, R.; Jucker, M. Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. J. Neurosci., 2005, 25, 11125-11132.
168. [168] Simard, A. R.; Soulet, D.; Gowing, G.; Julien, J. P.; Rivest, S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron, 2006, 49, 489-502.
169. [169] Ferrari, C. C.; Tarelli, R. Parkinson's disease and systemic inflammation. ParkinsonsDis., 2011, 2011, 436-813.
170. [170] Machado, A.; Herrera, A. J.; Venero, J. L.; Santiago, M.; De Pablos, R. M.; Villaran, R. F.; Espinosa-Oliva, A. M.; Arguelles, S.; Sarmiento, M.; Delgado-Cortes, M. J.; Maurino, R.; Cano, J. Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence. Parkinsons Dis., 2011, 2011, 393-769.
171. [171] Pott Godoy, M. C.; Tarelli, R.; Ferrari, C. C.; Sarchi, M. I.; Pitossi, F. J. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain, 2008, 131, 1880-1894.
172. [172] Villaran, R. F.; Espinosa-Oliva, A. M.; Sarmiento, M.; De Pablos, R. M.; Arguelles, S.; Delgado-Cortes, M. J.; Sobrino, V.; Van Rooijen, N.; Venero, J. L.; Herrera, A. J.; Cano, J.; Machado, A. Ulcerative colitis exacerbates lipopolysaccharide-induced damage to the nigral dopaminergic system: potential risk factor in Parkinson's disease. J. Neurochem., 2010, 114, 1687-1700.
173. [173] Block, M. L.; Calderon-Garciduenas, L. Air pollution: mechanisms of neuroinflammation and CNS disease. Trends Neurosci., 2009, 32, 506-516.
174. [174] Qin, L.; Wu, X.; Block, M. L.; Liu, Y.; Breese, G. R.; Hong, J. S.; Knapp, D. J.; Crews, F. T. Systemic LPS causes chronic neuroin-flammation and progressive neurodegeneration. Glia, 2007, 55, 453-462.
175. [175] Dantzer, R.; O'Connor, J. C.; Freund, G. G.; Johnson, R. W.; Kel-ley, K. W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci., 2008, 9, 46-56.
176. [176] Hernandez-Romero, M. C.; Delgado-Cortes, M. J.; Sarmiento, M.; de Pablos, R. M.; Espinosa-Oliva, A. M.; Arguelles, S.; Bandez, M. J.; Villaran, R. F.; Maurino, R.; Santiago, M.; Venero, J. L.; Herrera, A. J.; Cano, J.; Machado, A. Peripheral inflammation increases the deleterious effect of CNS inflammation on the nigros-triatal dopaminergic system. Neurotoxicology, 2012, 33, 347-360.
177. [177] Jang, H.; Boltz, D.; Sturm-Ramirez, K.; Shepherd, K. R.; Jiao, Y.; Webster, R.; Smeyne, R. J. Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflam-mation and neurodegeneration. Proc. Natl. Acad. Sci. U. S. A, 2009, 106, 14063-14068.
178. [178] Shoji, H.; Watanabe, M.; Itoh, S.; Kuwahara, H.; Hattori, F. Japanese encephalitis and parkinsonism. J. Neurol., 1993, 240, 59-60.
179. [179] Dale, R. C.; Church, A. J.; Surtees, R. A.; Lees, A. J.; Adcock, J. E.; Harding, B.; Neville, B. G.; Giovannoni, G. Encephalitis lethar-gica syndrome: 20 new cases and evidence of basal ganglia auto-immunity. Brain, 2004, 127, 21-33.
180. [180] Shu, X.; Wang, G.; Lu, X.; Xie, Y. Rheumatoid-like deformities in Parkinson's disease with 1-year follow-up: case report and literature review. Rheumatol. Int., 2010, 30, 1493-1497.
181. [181] Ertan, S.; Fresko, I.; Apaydin, H.; Ozekmekci, S.; Yazici, H. Ex-trapyramidal type rigidity in rheumatoid arthritis. Rheumatology (Oxford), 1999, 38, 627-630.
182. [182] Biessels, G. J.; Staekenborg, S.; Brunner, E.; Brayne, C.; Scheltens, P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol., 2006, 5, 64-74.
183. [183] Kloppenborg, R. P.; van den Berg, E.; Kappelle, L. J.; Biessels, G. J. Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur. J. Pharmacol., 2008, 585, 97-108.
184. [184] Kopf, D.; Frolich, L. Risk of incident Alzheimer's disease in diabetic patients: a systematic review of prospective trials. J. Alzheimers Dis., 2009, 16, 677-685.
185. [185] Xu, W. L.; Qiu, C. X.; Wahlin, A.; Winblad, B.; Fratiglioni, L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology, 2004, 63, 1181-1186.
186. [186] Jabir, N. R.; Firoz, C. K.; Baeesa, S. S.; Ashraf, G. M.; Akhtar, S.; Kamal, W.; Kamal, M. A.; Tabrez, S. Synopsis on the linkage of Alzheimer's and Parkinson's disease with chronic diseases. CNS Neurosci. Ther., 2015, 21, 1-7.
187. [187] Santiago, J. A.; Potashkin, J. A. System-based approaches to decode the molecular links in Parkinson's disease and diabetes. Neu-robiol. Dis., 2014, 72 Pt A, 84-91.
188. [188] Palacios, N.; Gao, X.; McCullough, M. L.; Jacobs, E. J.; Patel, A. V.; Mayo, T.; Schwarzschild, M. A.; Ascherio, A. Obesity, diabetes, and risk of Parkinson's disease. Mov. Disord., 2011, 26, 2253-2259.
189. [189] Savica, R.; Grossardt, B. R.; Ahlskog, J. E.; Rocca, W. A. Metabolic markers or conditions preceding Parkinson's disease: a case- control study. Mov. Disord., 2012, 27, 974-979.
190. [190] Santiago, J. A.; Potashkin, J. A. Shared dysregulated pathways lead to Parkinson's disease and diabetes. Trends Mol. Med., 2013, 19, 176-186.
191. [191] Hu, G.; Jousilahti, P.; Bidel, S.; Antikainen, R.; Tuomilehto, J. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care, 2007, 30, 842-847.
192. [192] Xu, Q.; Park, Y.; Huang, X.; Hollenbeck, A.; Blair, A.; Schatzkin, A.; Chen, H. Diabetes and risk of Parkinson's disease. Diabetes Care, 2011, 34, 910-915.
193. [193] Strand, B. H.; Langballe, E. M.; Hjellvik, V.; Handal, M.; Naess, O.; Knudsen, G. P.; Refsum, H.; Tambs, K.; Nafstad, P.; Schirmer, H.; Bergem, A. L.; Selmer, R.; Engedal, K.; Magnus, P.; Bjertness, E.; GENIDEM-Group Midlife vascular risk factors and their association with dementia deaths: results from a Norwegian prospective study followed up for 35 years. J. Neurol. Sci., 2013, 324, 124-130.
194. [194] Alonso, A.; Jacobs, D. R.; Menotti, A.; Nissinen, A.; Dontas, A.; Kafatos, A.; Kromhout, D. Cardiovascular risk factors and dementia mortality: 40 years of follow-up in the Seven Countries Study. J. Neurol. Sci., 2009, 280, 79-83.
195. [195] Newman, A. B.; Fitzpatrick, A. L.; Lopez, O.; Jackson, S.; Lyket-sos, C.; Jagust, W.; Ives, D.; Dekosky, S. T.; Kuller, L. H. Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J. Am. Geriatr. Soc., 2005, 53, 1101-1107.
196. [196] Jabir, N. R.; Kamal, M. A.; Abuzenadah, A. M.; Gan, S. H.; Alama, M. N.; Baeesa, S. S.; Tabrez, S. Alzheimer's and type 2 diabetes treatment via common enzyme targeting. CNS Neurol. Disord. Drug Targets, 2014, 13, 299-304.
197. [197] Humpel, C. Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease? Exp. Gerontol., 2011, 46, 225-232.
198. [198] Strang, R. R. The Association of Gastro-Duodenal Ulceration and Parkinson's Disease. Med. J. Aust., 1965, 1, 842-843.
199. [199] Weller, C.; Oxlade, N.; Dobbs, S. M.; Dobbs, R. J.; Charlett, A.; Bjarnason, I. T. Role of inflammation in gastrointestinal tract in aetiology and pathogenesis of idiopathic parkinsonism. FEMS Immunol. Med. Microbiol., 2005, 44, 129-135.
200. [200] Megraud, F. Epidemiology of Helicobacter pylori infection. Gastroenterol. Clin. North Am., 1993, 22, 73-88.
201. [201] M. Johnson, K. Lithgo, T. Price Is there an association between inflammatory bowel disease and Parkinson's disease? Epidemiology, 2014, P611.
202. [202] Bihari, K.; Lees, A. J. Cigarette smoking, Parkinson's disease and ulcerative colitis. J. Neurol. Neurosurg. Psychiatry, 1987, 50, 635.
203. [203] Mayer, E. A. Gut feelings: the emerging biology of gut-brain communication. Nat. Rev. Neurosci., 2011, 12, 453-466.
204. [204] Devos, D.; Lebouvier, T.; Lardeux, B.; Biraud, M.; Rouaud, T.; Pouclet, H.; Coron, E.; Bruley des Varannes, S.; Naveilhan, P.; Nguyen, J. M.; Neunlist, M.; Derkinderen, P. Colonic inflammation in Parkinson's disease. Neurobiol. Dis., 2013, 50, 42-48.
205. [205] Braak, H.; Rub, U.; Gai, W. P.; Del Tredici, K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm., 2003, 110, 517-536.
206. [206] Barrett, J. C.; Hansoul, S.; Nicolae, D. L.; Cho, J. H.; Duerr, R. H.; Rioux, J. D.; Brant, S. R.; Silverberg, M. S.; Taylor, K. D.; Bar-mada, M. M.; Bitton, A.; Dassopoulos, T.; Datta, L. W.; Green, T.; Griffiths, A. M.; Kistner, E. O.; Murtha, M. T.; Regueiro, M. D.; Rotter, J. I.; Schumm, L. P.; Steinhart, A. H.; Targan, S. R.; Xavier, R. J.; NIDDK IBD Genetics Consortium; Libioulle, C.; Sandor, C.; Lathrop, M.; Belaiche, J.; Dewit, O.; Gut, I.; Heath, S.; Laukens, D.; Mni, M.; Rutgeerts, P.; Van Gossum, A.; Zelenika, D.; Fran-chimont, D.; Hugot, J. P.; de Vos, M.; Vermeire, S.; Louis, E.; Belgian-French IBD Consortium; Wellcome Trust Case Control Consortium; Cardon, L. R.; Anderson, C. A.; Drummond, H.; Nimmo, E.; Ahmad, T.; Prescott, N. J.; Onnie, C. M.; Fisher, S. A.; Mar-chini, J.; Ghori, J.; Bumpstead, S.; Gwilliam, R.; Tremelling, M.; Deloukas, P.; Mansfield, J.; Jewell, D.; Satsangi, J.; Mathew, C. G.; Parkes, M.; Georges, M.; Daly, M. J. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet., 2008, 40, 955-962.
207. [207] Kitada, T.; Asakawa, S.; Hattori, N.; Matsumine, H.; Yamamura, Y.; Minoshima, S.; Yokochi, M.; Mizuno, Y.; Shimizu, N. Mutations in the parkin gene cause autosomal recessive juvenile parkin- sonism. Nature, 1998, 392, 605-608.
208. [208] Frank-Cannon, T. C.; Tran, T.; Ruhn, K. A.; Martinez, T. N.; Hong, J.; Marvin, M.; Hartley, M.; Trevino, I.; O'Brien, D. E.; Casey, B.; Goldberg, M. S.; Tansey, M. G. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J. Neurosci., 2008, 28, 10825-10834.
209. [209] Minghetti, L. Role of inflammation in neurodegenerative diseases. Curr. Opin. Neurol., 2005, 18, 315-321.
210. [210] Teeling, J. L.; Cunningham, C.; Newman, T. A.; Perry, V. H. The effect of non-steroidal anti-inflammatory agents on behavioural changes and cytokine production following systemic inflammation: Implications for a role of COX-1. Brain Behav. Immun., 2010, 24, 409-419.
211. [211] Qin, L.; He, J.; Hanes, R. N.; Pluzarev, O.; Hong, J. S.; Crews, F. T. Increased systemic and brain cytokine production and neuroin-flammation by endotoxin following ethanol treatment. J. Neuroin-flammation, 2008, 5, 10-2094-5-10.
212. [212] Borges, S.; Gayer-Anderson, C.; Mondelli, V. A systematic review of the activity of the hypothalamic-pituitary-adrenal axis in first episode psychosis. Psychoneuroendocrinology, 2013, 38, 603-611.
213. [213] Kessing, L. V.; Willer, I. S.; Knorr, U. Volume of the adrenal and pituitary glands in depression. Psychoneuroendocrinology, 2011, 36, 19-27.
214. [214] Kalsbeek, A.; van der Spek, R.; Lei, J.; Endert, E.; Buijs, R. M.; Fliers, E. Circadian rhythms in the hypothalamo-pituitary-adrenal (HPA) axis. Mol. Cell. Endocrinol., 2012, 349, 20-29.
215. [215] Licinio, J.; Frost, P. The neuroimmune-endocrine axis: pathophysi-ological implications for the central nervous system cytokines and hypothalamus-pituitary-adrenal hormone dynamics. Braz. J. Med. Biol. Res., 2000, 33, 1141-1148.
216. [216] Seifert, G.; Schilling, K.; Steinhauser, C. Astrocyte dysfunction in neurological disorders: a molecular perspective. Nat. Rev. Neuro-sci., 2006, 7, 194-206.
217. [217] Springer, T. A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell, 1994, 76, 301-314.
218. [218] Kim, M.; Carman, C. V.; Springer, T. A. Bidirectional transmem-brane signaling by cytoplasmic domain separation in integrins. Science, 2003, 301, 1720-1725.
219. [219] Morita, S.; Miyata, S. Different vascular permeability between the sensory and secretory circumventricular organs of adult mouse brain. Cell Tissue Res., 2012, 349, 589-603.
220. [220] Wertheimer, S. J.; Myers, C. L.; Wallace, R. W.; Parks, T. P. Intercellular adhesion molecule-1 gene expression in human endothelial cells. Differential regulation by tumor necrosis factor-alpha and phorbol myristate acetate. J. Biol. Chem., 1992, 267, 12030-12035.
221. [221] Proescholdt, M. G.; Chakravarty, S.; Foster, J. A.; Foti, S. B.; Briley, E. M.; Herkenham, M. Intracerebroventricular but not intravenous interleukin-1beta induces widespread vascular-mediated leukocyte infiltration and immune signal mRNA expression followed by brain-wide glial activation. Neuroscience, 2002, 112, 731-749.
222. [222] Corti, R.; Hutter, R.; Badimon, J. J.; Fuster, V. Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. J. Thromb. Thrombolysis, 2004, 17, 35-44.
223. [223] Villaran, R. F.; Espinosa-Oliva, A. M.; Sarmiento, M.; De Pablos, R. M.; Arguelles, S.; Delgado-Cortes, M. J.; Sobrino, V.; Van Rooijen, N.; Venero, J. L.; Herrera, A. J.; Cano, J.; Machado, A. Ulcerative colitis exacerbates lipopolysaccharide-induced damage to the nigral dopaminergic system: potential risk factor in Parkinson's disease. J. Neurochem., 2010, 114, 1687-1700.
224. [224] Alvarez, J. I.; Cayrol, R.; Prat, A. Disruption of central nervous system barriers in multiple sclerosis. Biochim. Biophys. Acta, 2011, 1812, 252-264.
225. [225] Lv, S.; Song, H. L.; Zhou, Y.; Li, L. X.; Cui, W.; Wang, W.; Liu, P. Tumour necrosis factor-alpha affects blood-brain barrier permeability and tight junction-associated occludin in acute liver failure. Liver Int., 2010, 30, 1198-1210.
226. [226] Wong, D.; Prameya, R.; Dorovini-Zis, K. Adhesion and migration of polymorphonuclear leukocytes across human brain microvessel endothelial cells are differentially regulated by endothelial cell adhesion molecules and modulate monolayer permeability. J. Neuro-immunol., 2007, 184, 136-148.
227. [227] Wosik, K.; Biernacki, K.; Khouzam, M. P.; Prat, A. Death receptor expression and function at the human blood brain barrier. J. Neu-rol. Sci., 2007, 259, 53-60.
228. [228] Cayrol, R.; Wosik, K.; Berard, J. L.; Dodelet-Devillers, A.; Ifergan, I.; Kebir, H.; Haqqani, A. S.; Kreymborg, K.; Krug, S.; Moumdjian, R.; Bouthillier, A.; Becher, B.; Arbour, N.; David, S.; Stanimirovic, D.; Prat, A. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat. Immunol., 2008, 9, 137-145.
229. [229] Larochelle C, Cayrol R, Kebir H et al MCAM/CD146 defines and regulates the function of a population of human effector memory Th17 lymphocytes subset involved in neuroinflammation. Clin. Immunol., 2010, S122, 135.
230. [230] Furness JB The Enteric Nervous System; Blackwell: Oxford, 2006.
231. [231] Gershom MD The Second Brain; Harper Collins: New York, 1998.
232. [232] Berthoud, H. R.; Neuhuber, W. L. Functional and chemical anatomy of the afferent vagal system. Auton. Neurosci., 2000, 85, 1-17.
233. [233] Collins, S. M.; Surette, M.; Bercik, P. The interplay between the intestinal microbiota and the brain. Nat. Rev. Microbiol., 2012, 10, 735-742.
234. [234] Diano, S.; Farr, S. A.; Benoit, S. C.; McNay, E. C.; da Silva, I.; Horvath, B.; Gaskin, F. S.; Nonaka, N.; Jaeger, L. B.; Banks, W. A.; Morley, J. E.; Pinto, S.; Sherwin, R. S.; Xu, L.; Yamada, K. A.; Sleeman, M. W.; Tschop, M. H.; Horvath, T. L. Ghrelin controls hippocampal spine synapse density and memory performance. Nat. Neuro sci., 2006, 9, 381-388.
235. [235] Berthoud, H. R. Vagal and hormonal gut-brain communication: from satiation to satisfaction. Neurogastroenterol. Motil, 2008, 20 Suppl 1, 64-72.
236. [236] Bercik, P.; Denou, E.; Collins, J.; Jackson, W.; Lu, J.; Jury, J.; Deng, Y.; Blennerhassett, P.; Macri, J.; McCoy, K. D.; Verdu, E. F.; Collins, S. M. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology, 2011, 141, 599-609, 609.e1-3.
237. [237] Schiano, T. D. Treatment options for hepatic encephalopathy. Pharmacotherapy, 2010, 30, 16S-21S.
238. [238] Abouesh, A.; Stone, C.; Hobbs, W. R. Antimicrobial-induced mania (antibiomania): a review of spontaneous reports. J. Clin. Psy-chopharmacol., 2002, 22, 71-81.
239. [239] Spillantini, M. G.; Schmidt, M. L.; Lee, V. M.; Trojanowski, J. Q.; Jakes, R.; Goedert, M. Alpha-synuclein in Lewy bodies. Nature, 1997, 388, 839-840.
240. [240] Bove, J.; Prou, D.; Perier, C.; Przedborski, S. Toxin-induced models of Parkinson's disease. Neuro Rx, 2005, 2, 484-494.
241. [241] Shannon, K. M.; Keshavarzian, A.; Mutlu, E.; Dodiya, H. B.; Daian, D.; Jaglin, J. A.; Kordower, J. H. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov. Disord., 2012, 27, 709-715.
242. [242] Beach, T. G.; Adler, C. H.; Sue, L. I.; Vedders, L.; Lue, L.; White Iii, C. L.; Akiyama, H.; Caviness, J. N.; Shill, H. A.; Sabbagh, M. N.; Walker, D. G.; Arizona Parkinson's Disease Consortium Multi-organ distribution of phosphorylated alpha-synuclein histopathol-ogy in subjects with Lewy body disorders. Acta Neuropathol., 2010, 119, 689-702.
243. [243] Braak, H.; de Vos, R. A.; Bohl, J.; Del Tredici, K. Gastric alpha- synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci. Lett., 2006, 396, 67-72.
244. [244] Wakabayashi, K.; Takahashi, H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur. Neurol., 1997, 38 Suppl 2, 2-7.
245. [245] Takeda, S.; Yamazaki, K.; Miyakawa, T.; Arai, H. Parkinson's disease with involvement of the parasympathetic ganglia. Acta Neuropathol., 1993, 86, 397-398.
246. [246] Wakabayashi, K.; Takahashi, H.; Takeda, S.; Ohama, E.; Ikuta, F. Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol., 1988, 76, 217-221.
247. [247] Wakabayashi, K.; Takahashi, H.; Ohama, E.; Ikuta, F. Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol., 1990, 79, 581-583.
248. [248] Shannon, K. M.; Keshavarzian, A.; Dodiya, H. B.; Jakate, S.; Kor-dower, J. H. Is alpha-synuclein in the colon a biomarker for premo-tor Parkinson's disease? Evidence from 3 cases. Mov. Disord., 2012, 27, 716-719.
249. [249] Qualman, S. J.; Haupt, H. M.; Yang, P.; Hamilton, S. R. Esophag- eal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease. Gastroenterology, 1984, 87, 848-856.
250. [250] Gray, M. T.; Gray, D. A.; Woulfe, J. M. Reply to: alimentary, my dear Watson? The challenges of enteric alpha-synuclein as a Parkinson's disease biomarker. Mov. Disord., 2014, 29, 1224-1225.
251. [251] Visanji, N. P.; Marras, C.; Hazrati, L. N.; Liu, L. W.; Lang, A. E. Alimentary, my dear Watson? The challenges of enteric alpha-synuclein as a Parkinson's disease biomarker. Mov. Disord., 2014, 29, 444-450.
252. [252] Kelly, L. P.; Carvey, P. M.; Keshavarzian, A.; Shannon, K. M.; Shaikh, M.; Bakay, R. A.; Kordower, J. H. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. Mov. Disord., 2014, 29, 999-1009.
253. [253] Bjarnason, I.; MacPherson, A.; Hollander, D. Intestinal permeability: an overview. Gastroenterology, 1995, 108, 1566-1581.
254. [254] Keita, A. V.; Soderholm, J. D. The intestinal barrier and its regulation by neuroimmune factors. Neurogastroenterol. Motil, 2010, 22, 718-733.
255. [255] Couch, Y.; Alvarez-Erviti, L.; Sibson, N. R.; Wood, M. J.; Anthony, D. C. The acute inflammatory response to intranigral alpha-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. J. Neuroinflammation, 2011, 8, 166-2094-8-166.
256. [256] Braak, H.; Del Tredici, K.; Rub, U.; de Vos, R. A.; Jansen Steur, E. N.; Braak, E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging, 2003, 24, 197-211.
257. [257] Visanji, N. P.; Brooks, P. L.; Hazrati, L. N.; Lang, A. E. The prion hypothesis in Parkinson's disease: Braak to the future. Acta Neuropathol. Commun., 2013, 1, 2-5960-1-2.
258. [258] Aguzzi, A.; Rajendran, L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron, 2009, 64, 783-790.
259. [259] Brundin, P.; Melki, R.; Kopito, R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat. Rev. Mol. Cell Biol., 2010, 11, 301-307.
260. [260] Polymenidou, M.; Cleveland, D. W. The seeds of neurodegenera- tion: prion-like spreading in ALS. Cell, 2011, 147, 498-508.
261. [261] Guo, J. L.; Lee, V. M. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat. Med., 2014, 20, 130-138.
262. [262] Yonetani, M.; Nonaka, T.; Masuda, M.; Inukai, Y.; Oikawa, T.; Hisanaga, S.; Hasegawa, M. Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. J. Biol. Chem., 2009, 284, 7940-7950.
263. [263] Heneka, M. T.; Kummer, M. P.; Latz, E. Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol., 2014, 14, 463-477.
264. [265] Jin, J. J.; Kim, H. D.; Maxwell, J. A.; Li, L.; Fukuchi, K. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J. Neuroinflammation, 2008, 5, 23-2094-5-23.
265. [266] Latz, E.; Xiao, T. S.; Stutz, A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol., 2013, 13, 397-411.
266. [267] Stewart, C. R.; Stuart, L. M.; Wilkinson, K.; van Gils, J. M.; Deng, J.; Halle, A.; Rayner, K. J.; Boyer, L.; Zhong, R.; Frazier, W. A.; Lacy-Hulbert, A.; El Khoury, J.; Golenbock, D. T.; Moore, K. J. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol., 2010, 11, 155-161.
267. [268] Strowig, T.; Henao-Mejia, J.; Elinav, E.; Flavell, R. Inflamma-somes in health and disease. Nature, 2012, 481, 278-286.
268. [269] Udan, M. L.; Ajit, D.; Crouse, N. R.; Nichols, M. R. Toll-like receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line. J. Neurochem., 2008, 104, 524-533.
269. [270] Shin, J. N.; Fattah, E. A.; Bhattacharya, A.; Ko, S.; Eissa, N. T. Inflammasome activation by altered proteostasis. J. Biol. Chem., 2013, 288, 35886-35895.
270. [271] He, C.; Tsuchiyama, S. K.; Nguyen, Q. T.; Plyusnina, E. N.; Terrill, S. R.; Sahibzada, S.; Patel, B.; Faulkner, A. R.; Shaposh- nikov, M. V.; Tian, R.; Tsuchiya, M.; Kaeberlein, M.; Moskalev, A. A.; Kennedy, B. K.; Polymenis, M. Enhanced longevity by ibu-profen, conserved in multiple species, occurs in yeast through inhibition of tryptophan import. PLoS Genet., 2014, 10, e1004860